<qa>  What is the primary endpoint of the study?The purpose of this study is to evaluate the effect of tobramycin inhalation solution TIS once daily compared tot placebo in patients with non-CF bronchiectasis. The primary endpoint is a reduction of exacerbations of the disease during the treatment period. Next to this parameter the investigators expect to show a significant beneficial effect on lung function parameters, QoL, bacterial load of pathogens in sputum and tobramycin resistance. 